Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07379216

Efficacy Evaluation Study of Vitamin C and Glutathione Liquid Sachet

The objective of this study is to evaluate the effect of liquid vitamin C and glutathione supplements on human skin condition improvement and anti-oxidation.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Skin Condition Anti-Oxidative Stress Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Chia Nan University of Pharmacy & Science

Pingtung City, 928, Taiwan

Location status: Recruiting

Location contact

Chia-Hua Liang, Ph.D.

CONTACT

[email protected]

+886-06-2664911 ext. 2441

Chia-Hua Liang, Ph.D.

PRINCIPAL_INVESTIGATOR

About this study

This study is a single-center, placebo-controlled, double-blinded, parallel human trial designed to evaluate the skin beauty and anti-oxidant effect of liquid vitamin C and glutathione supplements.

Healthy adult participants aged 18-65 years will be enrolled. Participants will be informed to consume test samples daily for 12 consecutive weeks. Skin measurement and self-assessment questionnaires will be conducted at baseline (before intake), after 4, 8 weeks, and 12 weeks of consumption. Fasting blood samples will be collected at baseline and after 12 weeks of consumption.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male or female adults, aged 18-65 years old;
  • Commitment not to use products having activity comparable with that of the product to be tested during the study period;
  • Free of any dermatological or systemic disorder that would interfere with results.

Exclusion criteria

  • Subject with obvious skin surface damage;
  • Subject who had oral or topical medication which may affect skin condition within 1 month;
  • Individuals with known allergies to cosmetics, medications, or foods (especially those allergic to legumes/soy);
  • Pregnant or breastfeeding individuals;
  • Received facial laser therapy, chemical peeling in the past 2 months.
  • Individuals unwilling to allow publication or public disclosure of photographs taken as part of the study results

Treatment and study plan

Placebo sachet

Dietary Supplement

consume 1 sachet of the test samples daily for 12 consecutive weeks

Vitamin C and Glutathione Liquid Sachet

Dietary Supplement

consume 1 sachet of the test samples daily for 12 consecutive weeks

Other names: Lipo GLUTA-C

Primary outcomes

  1. The change of skin tone

    Time frame: Change from Baseline skin tone at 12 weeks

    Chroma Meter MM500 was utilized to measure face skin tone. Units: Individual Typology Angle (ITA°)

  2. The change of visible spots

    Time frame: Change from Baseline visible spots at 12 weeks

    VISIA Complexion Analysis was utilized to measure visible spots on face. Units: the amount of detectable visible spots

  3. The change of UV spots

    Time frame: Change from Baseline UV spots at 12 weeks

    VISIA Complexion Analysis was utilized to measure UV spots on face. Units: the amount of detectable UV spots

Secondary outcomes

  1. The change of skin hydration

    Time frame: Change from Baseline skin hydration at 12 weeks

    Corneometer® CM825 (CK, Germany) was utilized to measure skin surface hydation. Units: arbitrary Corneometer® units 0-120.

  2. The change of skin redness

    Time frame: Change from Baseline skin redness at 12 weeks

    Chroma Meter MM500 was utilized to measure face skin redness. Units: a* value

  3. The change of skin melanin index

    Time frame: Change from Baseline skin melanin index at 12 weeks

    Mexameter® MX18 (CK, Germany) was utilized to measure face skin melanin level. Units: arbitrary units

  4. The change of skin elasticity

    Time frame: Change from Baseline skin elasticity at 12 weeks

    Skin elasticity (Softplus, Italy) was utilized to measure face skin elasticity. Units: arbitrary units

  5. The change of brown spots

    Time frame: Change from Baseline brown spots at 12 weeks

    VISIA Complexion Analysis was utilized to measure brown spots on face. Units: the amount of detectable brown spots

  6. The change of wrinkles around the eyes

    Time frame: Change from Baseline wrinkles around the eyes at 12 weeks

    VISIA Complexion Analysis was utilized to measure wrinkles around the eyes. Units: the amount of detectable wrinkles

  7. The change of skin texture

    Time frame: Change from Baseline skin texture at 12 weeks

    VISIA Complexion Analysis was utilized to measure skin texture. Units: arbitrary units

  8. The change of skin collagen density

    Time frame: Change from Baseline skin collagen density at 12 weeks

    DermaLab® Series SkinLab Combo was utilized to measure skin collagen density. Units: arbitrary units

  9. The change of total antioxidation capacity (TAC)

    Time frame: Change from Baseline TAC at 12 weeks

    A fasting blood sample will be collected for TAC testing.

  10. The change of Superoxide Dismutase (SOD)

    Time frame: Change from Baseline SOD at 12 weeks

    A fasting blood sample will be collected for SOD testing.

  11. The change of Glutathione S-transferase-Red Blood Cells (GST-RBC)

    Time frame: Change from Baseline GST-RBC at 12 weeks

    A fasting blood sample will be collected for GST-RBC testing.

  12. The change of Malondialdehyde (MDA)

    Time frame: Change from Baseline MDA at 12 weeks

    A fasting blood sample will be collected for MDA testing.

Other outcomes

  1. The change of self-assessment skin condition

    Time frame: Change from Baseline skin condition at 12 weeks

    Skin condition was evaluated using a 5-point Likert scale (0-4) to assess the severity of skin-related symptoms. The scale was defined as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.

  2. The change of self-assessment fatigue level

    Time frame: Change from Baseline fatigue level at 12 weeks

    Fatigue Symptom Inventory (FSI) was collected and evaluate fatigue level. Most items are rated on an 11-point Likert scale ranging from 0 to 10. The scores are generally averaged to create subscales for intensity and interference.

  3. The change of self-assessment Low Immunity level

    Time frame: Change from Baseline Low Immunity level at 12 weeks

    Low Immunity level was evaluated using a 5-point Likert scale (0-4) to assess the severity of Low Immunity-related symptoms. The scale was defined as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.

  4. The change of blood liver function biomarkers (AST, ALT)

    Time frame: Change from Baseline liver function biomarkers at 12 weeks

    A fasting blood sample will be collected for liver function biomarkers testing.

  5. The change of blood renal function biomarkers (creatinine, BUN)

    Time frame: Change from Baseline renal function biomarkers at 12 weeks

    A fasting blood sample will be collected for renal function biomarkers testing.

Study contacts

Contact information is provided by the study sponsor or research team.

Chia-Hua Liang, Ph.D.

CONTACT

[email protected]

+886-06-2664911 ext. 2441

Ping Lin

CONTACT

[email protected]

+886-02-87977811

Sponsors and collaborators

Lead sponsor

TCI Co., Ltd.

Industry

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jan 30, 2026
Registry last updated
Feb 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.